20 mayo 2015
A new drug combination showed an advantage in three of a total of 10 patient groups with hepatitis C, particularly regarding virologic response, reviewers have found. The extent of added benefit remains unclear, however.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/FFE-AZeiCQw/150520100015.htm
